“Ten-Year Response to Crizotinib in ALK-positive Inflammatory Myofibroblastic Tumors: Case Reports” (2024) Voprosy onkologii, 70(2), pp. 384–389. doi:10.37469/0507-3758-2024-70-2-384-389.